Compare Fidelity National Information Servcs Inc (FIS) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fidelity National Information Servcs Inc vs Summit Therapeutics Inc — how do they compare? Fidelity National Information Servcs Inc trades at $33.98 (market cap $17.71B), while Summit Therapeutics Inc trades at $17.42 (market cap $13.71B). The key difference: Fidelity National Information Servcs Inc is the larger of the two by market cap, and Fidelity National Information Servcs Inc pays a 5.13% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fidelity National Information Servcs Inc for 88 Days and Summit Therapeutics Inc for 16 Days on average.
| FIS | SMMT | |
|---|---|---|
Market Cap | $17.71B | $13.71B |
Volume | 9,047,825 | 6,173,057 |
Sector | Technology | Health |
52-Week High | $68.57 | $26.38 |
52-Week Low | $32.44 | $12.43 |
Typical Hold Time | 88 Days | 16 Days |
Enterprise Value | $38.22B | $13.04B |
Dividend Yield | 5.13% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIS trades at $34.19, up 1.09% with bearish technical signals but strong fundamentals including a low P/E of 5.27 and net income margin of 27.65%. Recent earnings show mixed results with Q1 and Q2 beats but a Q4 miss. The company demonstrates business momentum with multiple core banking wins and product launches, including embedded banking platform and cloud modernization initiatives announced in September 2026.
FIS presents a compelling value opportunity with attractive valuation metrics and improving profitability, though technical indicators suggest near-term pressure. The 37% upside to consensus price target of $47.15 and strong analyst support (57% buy ratings) indicate Wall Street optimism, balanced by debt concerns and competitive fintech landscape requiring careful monitoring.
Summit Therapeutics (SMMT) trades at $17.29, down 3.68% on the day, amid a bullish technical signal driven by moving averages. The company reported no revenue and a net loss of $1.08 billion in 2025, with negative profitability ratios, but recent news of a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations has boosted investor optimism.
The outlook is speculative, with significant upside potential based on the $29.33 analyst consensus price target, but high execution risk remains as the company is pre-revenue and reliant on clinical trial success. Key catalysts include upcoming trial results for ivonescimab, while risks involve drug development setbacks and cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fidelity National Information Servcs Inc
Fidelity National Information Services' legacy operations provide core and payment processing services to banks, but its business has expanded over time. By acquiring Sungard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS now provides payment processing services for merchants and holds leading positions in the United States and United Kingdom. About a fourth of revenue is generated outside North America.
Read more on FIS →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
